Somatostatin Regulation describes the physiological control over the secretion and action of somatostatin, a peptide hormone primarily produced in the hypothalamus and pancreas that functions as a potent inhibitor of various other hormones, most notably Growth Hormone (GH) and Insulin. Precise regulation is essential because somatostatin acts as a critical brake on the somatotropic axis, balancing the stimulatory effects of Growth Hormone-Releasing Hormone (GHRH). Dysregulation can lead to imbalances in growth and metabolism.
Origin
The term is a core concept in neuroendocrinology. Somatostatin, derived from the Greek soma (body) and stasis (stopping), literally means “growth-inhibiting factor.” “Regulation” refers to the complex feedback loops that control its release.
Mechanism
Hypothalamic somatostatin is tonically released to suppress pituitary GH secretion. The pulsatile nature of GH release is achieved by rhythmic, temporary drops in somatostatin secretion, allowing GHRH to exert its effect. Age-related decline in GH is often linked to an increase in somatostatin tone. Therefore, optimizing this regulation, often through GHRH secretagogues, aims to reduce somatostatin’s inhibitory effect and restore robust GH pulsatility.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.